Is BCDA or ARTL more profitable?

Artelo Biosciences' return on equity of -1,600.12% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Artelo Biosciences N/A -1,600.12% -224.62%

Which has preferable earnings & valuation, ARTL or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is ARTL or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate ARTL or BFRI?

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 3,637.02%. Given Artelo Biosciences' higher probable upside, equities research analysts clearly believe Artelo Biosciences is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ARTL or BON?

Artelo Biosciences presently has a consensus target price of $54.00, indicating a potential upside of 3,637.02%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Artelo Biosciences is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ARTL or BON?

Bon Natural Life has higher revenue and earnings than Artelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Bon Natural Life $18.67M 0.54 -$2M N/A N/A

Is ARTL or BON more profitable?

Bon Natural Life's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Bon Natural Life N/A N/A N/A

Which has better earnings and valuation, ARTL or CALC?

CalciMedica is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is ARTL or CALC more profitable?

CalciMedica's return on equity of -863.40% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% CalciMedica N/A -863.40% -144.33%

Artelo Biosciences (ARTL) Competitors

$1.44 -0.02 (-1.03%)

As of 03:03 PM Eastern

Compare

ARTL vs. BCDA, PHXM, BFRI, BON, and CALC

Should you buy Artelo Biosciences stock or one of its competitors? MarketBeat compares Artelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artelo Biosciences include BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Biofrontera (BFRI), Bon Natural Life (BON), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry.

How does Artelo Biosciences compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

20.6% of BioCardia shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 11.5% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioCardia's average media sentiment score of 1.62 beat Artelo Biosciences' score of 1.14 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Very Positive
Artelo Biosciences	Positive

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,617.39%. Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 3,637.02%. Given Artelo Biosciences' higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioCardia has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

Artelo Biosciences' return on equity of -1,600.12% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

BioCardia has higher revenue and earnings than Artelo Biosciences. BioCardia is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	174.49	-$8.23M	-$0.91	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Summary

BioCardia beats Artelo Biosciences on 9 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to PHAXIAM Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

PHAXIAM Therapeutics' return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
PHAXIAM Therapeutics	N/A	N/A	N/A

Artelo Biosciences presently has a consensus target price of $54.00, suggesting a potential upside of 3,637.02%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Artelo Biosciences is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 11.5% of Artelo Biosciences shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

In the previous week, Artelo Biosciences' average media sentiment score of 1.14 beat PHAXIAM Therapeutics' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Positive
PHAXIAM Therapeutics	Neutral

Artelo Biosciences has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Summary

Artelo Biosciences beats PHAXIAM Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Artelo Biosciences compare to Biofrontera?

Artelo Biosciences (NASDAQ:ARTL) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Artelo Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Artelo Biosciences has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Biofrontera's return on equity of -515.34% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Biofrontera	-25.66%	-515.34%	-53.91%

Biofrontera has higher revenue and earnings than Artelo Biosciences. Biofrontera is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Biofrontera	$41.71M	0.30	-$10.54M	-$0.97	N/A

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 3,637.02%. Given Artelo Biosciences' higher probable upside, equities research analysts clearly believe Artelo Biosciences is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 11.5% of Artelo Biosciences shares are held by company insiders. Comparatively, 4.8% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Biofrontera had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 1.14 beat Biofrontera's score of 0.91 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Positive
Biofrontera	Positive

Summary

Biofrontera beats Artelo Biosciences on 10 of the 15 factors compared between the two stocks.

How does Artelo Biosciences compare to Bon Natural Life?

Artelo Biosciences (NASDAQ:ARTL) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Bon Natural Life's average media sentiment score of 1.90 beat Artelo Biosciences' score of 1.14 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company	Overall Sentiment
Artelo Biosciences	Positive
Bon Natural Life	Very Positive

Artelo Biosciences presently has a consensus target price of $54.00, indicating a potential upside of 3,637.02%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Artelo Biosciences is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life has higher revenue and earnings than Artelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Bon Natural Life	$18.67M	0.54	-$2M	N/A	N/A

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 11.5% of Artelo Biosciences shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bon Natural Life's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Bon Natural Life	N/A	N/A	N/A

Artelo Biosciences has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

Summary

Bon Natural Life beats Artelo Biosciences on 6 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to CalciMedica?

Artelo Biosciences (NASDAQ:ARTL) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

0.9% of Artelo Biosciences shares are held by institutional investors. 11.5% of Artelo Biosciences shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CalciMedica's average media sentiment score of 1.87 beat Artelo Biosciences' score of 1.14 indicating that CalciMedica is being referred to more favorably in the news media.

Company	Overall Sentiment
Artelo Biosciences	Positive
CalciMedica	Very Positive

CalciMedica is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

Artelo Biosciences has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Artelo Biosciences currently has a consensus price target of $54.00, indicating a potential upside of 3,637.02%. CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,044.16%. Given Artelo Biosciences' higher possible upside, research analysts plainly believe Artelo Biosciences is more favorable than CalciMedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CalciMedica's return on equity of -863.40% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
CalciMedica	N/A	-863.40%	-144.33%

Summary

CalciMedica beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.37M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.04	18.86	23.86	24.42
Price / Sales	N/A	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	-0.76	6.81	10.04	6.74
Net Income	-$12.88M	$24.09M	$3.56B	$337.03M
7 Day Performance	-1.03%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-92.71%	48.97%	28.80%	34.36%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	2.708 of 5 stars	$1.45 -1.0%	$54.00 +3,637.0%	-92.3%	$3.37M	N/A	N/A	5	Short Interest Decrease Gap Up
BCDA BioCardia	3.6948 of 5 stars	$0.91 -4.6%	$25.00 +2,643.9%	-59.9%	$10.86M	$60K	N/A	40	Positive News
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
BFRI Biofrontera	0.8795 of 5 stars	$0.80 -1.5%	N/A	+48.2%	$10.34M	$41.71M	N/A	70	Analyst Upgrade
BON Bon Natural Life	0.6155 of 5 stars	$1.28 +0.8%	N/A	-27.5%	$10.32M	$18.67M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. BCDA, PHXM, BFRI, BON, and CALC

How does Artelo Biosciences compare to BioCardia?

Summary

How does Artelo Biosciences compare to PHAXIAM Therapeutics?

Summary

How does Artelo Biosciences compare to Biofrontera?

Summary

How does Artelo Biosciences compare to Bon Natural Life?

Summary

How does Artelo Biosciences compare to CalciMedica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. BCDA, PHXM, BFRI, BON, and CALC

How does Artelo Biosciences compare to BioCardia?

Do institutionals & insiders have more ownership in BCDA or ARTL?

Does the media prefer BCDA or ARTL?

Do analysts recommend BCDA or ARTL?

Which has more volatility & risk, BCDA or ARTL?

Is BCDA or ARTL more profitable?

Which has higher valuation and earnings, BCDA or ARTL?

Summary

How does Artelo Biosciences compare to PHAXIAM Therapeutics?

Is ARTL or PHXM more profitable?

Do analysts recommend ARTL or PHXM?

Do institutionals & insiders hold more shares of ARTL or PHXM?

Which has preferable earnings & valuation, ARTL or PHXM?

Does the media refer more to ARTL or PHXM?

Which has more volatility & risk, ARTL or PHXM?

Summary

How does Artelo Biosciences compare to Biofrontera?

Which has more risk & volatility, ARTL or BFRI?

Is ARTL or BFRI more profitable?

Which has preferable earnings & valuation, ARTL or BFRI?

Do analysts rate ARTL or BFRI?

Do insiders & institutionals have more ownership in ARTL or BFRI?

Does the media favor ARTL or BFRI?

Summary

How does Artelo Biosciences compare to Bon Natural Life?

Does the media refer more to ARTL or BON?

Do analysts rate ARTL or BON?

Which has stronger valuation & earnings, ARTL or BON?

Do insiders and institutionals have more ownership in ARTL or BON?

Is ARTL or BON more profitable?

Which has more volatility & risk, ARTL or BON?

Summary

How does Artelo Biosciences compare to CalciMedica?

Do institutionals & insiders have more ownership in ARTL or CALC?

Does the media refer more to ARTL or CALC?

Which has better earnings and valuation, ARTL or CALC?

Which has more volatility and risk, ARTL or CALC?

Do analysts rate ARTL or CALC?

Is ARTL or CALC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools